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Introduction {#sec1-1}
============

Endothelial progenitor cells (EPCs) are bone marrow-derived and lineage-specific cells committed to become mature endothelial cells. They are involved in vascular restoration and neovascularization in tissue damaged by traumatic, inflammatory or ischemic injury. The numbers of circulating EPCs are regulated in a variety of disease conditions; including diabetes, cancer, coronary artery disease and trauma (Madonna et al., 2017; Balistreri et al., 2018; Wang et al., 2018b). EPCs are mobilized from the bone marrow and enter the blood circulation to ultimately "home in" to the site of injury. Increased EPC mobilization and homing in contribute to neovascularization and promote new bone formation in fracture healing (Vafaei et al., 2017). Circulating EPC levels predict outcome in patients with atherosclerotic vascular disease and in patients with congestive heart failure (Chesnut et al., 1993; Rodriguez-Carrio et al., 2017; Elia et al., 2018). The increase in the number of circulating EPCs after acute ischemic stroke is also associated with good functional outcome and reduced infarct growth in the ischemic brain (Chesnut et al., 1993; Chen et al., 2009). However, the role of circulating EPCs remains unknown in patients with traumatic brain injury (TBI).

Many factors regulate EPC mobilization and function. Recent studies have found that hyperglycemia downregulates the number of circulating EPCs, accelerates EPC senescence and impairs EPC function (Kim and Kim, 2018; Stormann et al., 2018; Wang et al., 2018c; Yamashita et al., 2018). There is a growing body of experimental and clinical literature showing a significant association between persistent hyperglycemia and poor outcomes in different acute medical and surgical conditions (Yamashita et al., 2018). Blood glucose variability and hyperglycemia were associated with greater risk of both hospital death and prolonged duration of stay after brain injury (van Bommel et al., 2018). Hyperglycemia has been associated with worse outcome following TBI or cardiac surgery in adults, and is related with mortality in patients with severe TBI (Lemmey et al., 2018; Ng and Bax, 2018; Solymar et al., 2018). A previous investigation in our institute showed that numbers of circulating EPCs in 29 patients with TBI decreased and increased with time. Recently, we showed that CD34^+^ hematopoietic stem cells (EPCs are a subpopulation of CD34^+^ cells) accumulate in injured cerebral tissue and are competent to be incorporated into new vasculature in TBI rats (Rodriguez-Carrio et al., 2017; Zhao et al., 2018). However, it is not known whether the regulation of circulating EPCs after TBI is associated with blood glucose levels or functional outcome, and the relationship between blood glucose and circulating EPCs has not been fully investigated.

In this study, we performed a clinical investigation to measure blood glucose and the number of circulating EPCs in 101 TBI patients from 1 to 21 days after TBI. This large sample enabled us to conduct subgroup analyses to determine whether the number of circulating EPCs and blood glucose levels within 21 days after TBI relate to clinical TBI prognosis. This is the first study to demonstrate the relevance of circulating EPCs and blood glucose levels to clinical TBI prognosis.

Participants and Methods {#sec1-2}
========================

Design {#sec2-1}
------

A retrospective observation study.

Participants {#sec2-2}
------------

TBI patients admitted to Tianjin Medical University General Hospital and Tianjin Huanhu Hospital, China from April 2005 to March 2007 were enrolled. All patients were treated according to the guidelines for the management of severe TBI, 4^th^ Edition, USA, the latest clinical guidelines for management of traumatic brain injury (Pattuwage et al., 2017). The treatment strategy was made by two independent senior physicians. The indications for craniotomy were judged according to imaging and clinical symptoms. Craniotomy included decompression with extensive bone resection and removal of subdural hematoma. After surgery, hemostatic drugs and dehydration drugs were routinely used. During and after surgery, blood transfusion was given according to the clinical situation and blood parameters (hemoglobin less than 70 g/L). Blood transfusion components included erythrocyte suspension and fresh frozen plasma. This study was approved by the Ethical Committee of Tianjin Medical University General Hospital, China (approval No. 200501) in January 2015. All subjects or guardians provided informed written consent before enrollment.

### Inclusion criteria {#sec3-1}

\(1\) TBI was diagnosed by plain head computed tomography scan. (2) The ages of patients are 18 to 90 years. (3) The time from injury to admission were less than 3 hours.

### Exclusion criteria {#sec3-2}

Patients with complex trauma involving body trunk and limbs, hematological disorders, and cancer were excluded.

A total of 101 TBI patients and 37 age- and sex-matched healthy controls were recruited. Patients who received more than 1800 mL of blood transfusion (17 cases) were excluded from the study after a pilot study showed that the amount of blood transfusion remarkably affected circulating EPC numbers. As a result, data from 84 patients were analyzed.

Blood samples {#sec2-3}
-------------

Fasting venous blood (6 mL, taken in the morning) was collected at 1, 4, 7, 14, and 21 days after TBI using ethylenediaminetetraacetic acid (EDTA, 0.5 mM final concentration) as anti-coagulant. Blood samples were also collected from healthy controls to obtain baseline normal reference values. Blood samples were collected according to the University guidelines for collecting and using human samples. They were processed within 2 hours of collection to measure EPC and blood glucose levels in plasma. Blood glucose was measured with an automatic biochemical analyzer (7600; Hitachi, Tokyo, Japan; reagents from Roche Diagnostics, Mannheim, Germany).

EPCs measured by flow cytometry {#sec2-4}
-------------------------------

Whole blood samples (2 mL) were first subjected to Ficoll gradient centrifugation to isolate mononuclear cells as previously described (Liu et al., 2007). The isolated cells were suspended in phosphate-buffered saline (pH 7.2) containing 2 mM EDTA and incubated with an FITC-conjugated anti-CD34 antibody (BD Pharmingen, San Jose, CA, USA) and a PE-conjugated anti-CD133 antibody (Milerenyi Biotech, Gladbach, Germany) for 10 minutes at room temperature. The two antibodies were employed to ensure specific detection of "early" EPCs, which have great proliferation and differentiation capacities. Cells were analyzed by flow cytometry (Beckman Dickinson FACSCalibur system, BD Bioscience, San Jose, CA, USA). Two isotype controls of PE-and FITC-conjugated mouse immunoglobin Gs (IgGs) were used for background non-specific binding. Cells were first run on forward and side scatter to select mononuclear cells, and to reduce signal noises from cell aggregates, platelets and cellular debris. EPCs were then detected as the gated cells that were stained for FITC-CD34 and PE-CD133 and were quantified as the number of cells per 2 × 10^6^ mononuclear cells (**[Figure 1](#F1){ref-type="fig"}**).

![Flow cytometry for detection of CD34- and CD133-positive cells.\
Cells were first gated based on size and forward scatter. The black-and-white chart shows exclusion of platelets, dead cells, cell masses and cell fragments. The boxed area shows mononuclear cells to be analyzed (A). The gated cells were then collected *via* an FITC CD34-positive gate (boxed area in B). Mouse IgG1 conjugated with FITC or PE were used as isotype controls (the orange signal in C). The double-gated cells were then examined for CD133 and CD34 double-positive cells. The blue cells in the upper right quadrant are CD34 and CD133 double-positive cells (D). FITC: Fluorescein isothiocyanate; PE: phycoerythrin.](NRR-14-984-g002){#F1}

Statistical analysis {#sec2-5}
--------------------

All analysis was performed using SPSS 16.0 software (SPSS, Chicago, IL, USA) or the SAS statistical package (Version 8.1; SAS Institute, Cary, NC, USA). The data are expressed as the mean ± SEM for the continuous variables and as percentages for categorical variables. Categorical variables were compared using the Pearson's chi-square test. Comparisons between groups for continuous variables were analyzed using Student's *t*-test or one-way analysis of variance followed by the Student-Newman-Keuls *post hoc* test or repeated measures analysis of variance. Correlation between two continuous variables was performed using Pearson's correlation coefficients. In this clinical investigation, circulating EPCs and serum glucose levels were defined as independent variables and dependent variables, respectively. We analyzed the overall correlation between circulating EPCs and serum glucose at 1, 4 and 7 days after injury. A value of *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

Patient population {#sec2-6}
------------------

**[Table 1](#T1){ref-type="table"}** shows the overall study population including healthy subjects (*n* = 37) and TBI patients (*n* = 84). They were matched for age, sex, pre-medical history, smoking habits, alcohol consumption and medication.

###### 

Clinical characteristics of the study population

                            Healthy subjects (*n* = 37)   TBI patients (*n* = 84)   *P*
  ------------------------- ----------------------------- ------------------------- -------
  Age (years)               42.92±2.67 (24--72)           40.45±1.97 (18--85)       0.478
  Sex (female)              9(24.3)                       21(25)                    0.937
  Pre-medical history                                                               
   Hypertension             3(8.10)                       6(7.14)                   0.852
   Diabetes mellitus        1(2.70)                       2(2.38)                   0.916
   Hyperlipidemia           4(10.81)                      10(11.90)                 0.862
   Ischemic heart disease   1(2.70)                       1(1.19)                   0.548
   Stroke                   2(5.40)                       3(3.57)                   0.641
   Smoking habits           4(10.81)                      6(7.14)                   0.500
   Alcohol consumption      1(2.70)                       2(2.38)                   0.916
  Medication                                                                        
   Statins                  3(8.11)                       6(7.14)                   0.852
   Aspirin                  4(10.81)                      9(10.71)                  0.987
   Estrogen                 1(2.70)                       0                         0.130

Data are expressed as *n* (%) with the exception of age \[mean ± SEM (range)\]. Statistical significances of difference between groups were determined by Student's *t* test (continuous variables) or by chi-square test (categorical variables). TBI: Traumatic brain injury.

In total, 101 patients with TBI were initially recruited. Seventeen patients who received more than 1800 mL of blood transfusion were excluded, because the amount of transfused blood noticeably affects the levels of circulating EPCs (data not shown). **[Table 2](#T2){ref-type="table"}** shows that the circulating EPCs in the patients receiving less than 1800 mL blood transfusion (*n* = 27) were not statistically different from non-blood transfused patients (*n* = 57) at all five time points (repeated measure analysis of variance, blood transfused subjects versus non-blood transfused subjects, transfusion: *F* = 2.012, *P* = 0.160; time course: *F* = 7.659, *P* \< 0.05; the transfusion and time course interaction: *F* = 1.485, *P* = 0.206). Therefore, 84 TBI patients were enrolled for analysis.

###### 

Effect of blood transfusion and craniotomy on the numbers (*n*) of circulating endothelial progenitor cells

  Follow-up (day)   Blood transfusion   *P*          Craniotomy   *P*                       
  ----------------- ------------------- ------------ ------------ ------------ ------------ -------
  1                 49.9±10.8           62.8±5.5     0.239        62.1±6.7     51.5±7.4     0.339
  4                 88.0±13.7           93.0±9.4     0.763        99.3±10.6    74.6±8.0     0.136
  7                 125.9±24.4          130.8±11.4   0.835        131.7±14.9   124.0±13.5   0.700
  14                88.6±19.8           119.9±16.5   0.238        92.8±10.1    95.7±8.9     0.831
  21                102.8±30.6          93.1±16.2    0.786        78.1±6.9     94.8±7.2     0.098

Data are expressed as the mean ± SEM.

General changes in circulating EPC numbers in TBI patients and healthy subjects {#sec2-7}
-------------------------------------------------------------------------------

To test the changes in circulating EPCs after TBI, EPC numbers in peripheral blood were determined by flow cytometry at 1, 4, 7, 14 and 21 days after TBI. Blood samples were also collected from 37 healthy subjects as controls. The average circulating numbers of EPCs in patients were lower at 1 day after TBI compared with healthy subjects (**[Figure 2](#F2){ref-type="fig"}**). However, this number rapidly increased thereafter, reaching a peak 7 days post TBI and then gradually declining to the baseline level over the next 14 days (**[Figure 2](#F2){ref-type="fig"}**). Of 84 TBI patients, 57 underwent surgery to remove hematoma and/or to relieve intracranial hypertension and 27 patients received non-surgical treatments. As shown in **[Table 2](#T2){ref-type="table"}**, there was no significant difference between the patients that did or did not undergo craniotomy (57 craniotomy *versus* 27 non-craniotomy patients, treatment measure: *F* = 3.124, *P* = 0.112; time course: *F* = 8.734, *P* \< 0.01; the treatment measure and time course interaction: *F* = 1.713, *P* = 0.186). Therefore, we can exclude the effect of surgery and transfusion on circulating EPC numbers.

![General changes in the number of circulating EPCs after traumatic brain injury.\
Circulating EPCs were detected at 1, 4, 7, 14 and 21 days after traumatic brain injury (*n* = 84) and in normal control subjects (*n* = 37). EPC numbers in peripheral blood were significantly decreased at day 1 and increased at days 7 and 14 after traumatic brain injury (*P* \< 0.05). \**P* \< 0.05, *vs*. control group. Data are expressed as the mean ± SD (one-way analysis of variance followed by the Student-Newman-Keuls *post hoc* test). EPCs: endothelial progenitor cells.](NRR-14-984-g003){#F2}

Correlation between circulating EPCs numbers and serum glucose levels after TBI {#sec2-8}
-------------------------------------------------------------------------------

High glucose levels influence EPC homing, migration and function. To test the relationship between blood glucose levels and numbers of circulating EPCs, correlation analysis was performed (Kim et al., 2015). Blood glucose levels and EPC numbers were detected at 1, 4, 7, 14 and 21 days after TBI. As shown in **[Figure 3A](#F3){ref-type="fig"}**, serum glucose levels were noticeably increased at 1 day after TBI and then steadily decreased over the next 20 days of follow-up. The scatter plot showed that serum glucose level was negatively correlated with the number of circulating EPCs at 1, 4 and 7 days after TBI (**[Figure 3B](#F3){ref-type="fig"}**; *r* = --0.147, *P* = 0.019). To assess if high glucose reduced the number of circulating EPCs, the patients were divided into three subgroups according to the elevation of serum glucose at 1 day after TBI compared with the normal value in healthy subjects: a low glucose group whose increase of glucose was \< 0.92 mM; a medium glucose group whose increase of glucose was between 0.92 mM and 4.06 mM; and a higher glucose group whose increase of glucose was \> 4.06 mM. These data showed (**[Figure 4](#F4){ref-type="fig"}**) that the number of circulating EPCs was remarkably decreased in TBI patients with higher glucose compared to TBI patients with lower and medium levels of glucose. These data indicate that blood glucose levels are negatively correlated with circulating EPC numbers. Higher blood glucose correlates with lower numbers of circulating EPCs after TBI.

![Correlation between the number of circulating EPCs and serum glucose levels.\
(A) Comparison of circulating EPC numbers and serum glucose levels at 1, 4, 7, 14 and 21 days after traumatic brain injury. (B) The overall correlation between the number of circulating EPCs and serum glucose level at 1, 4 and 7 days after injury. In this clinical investigation, circulating EPC number and serum glucose levels are defined as independent variables and dependent variables, respectively. The scatter plot shows a significant negative correlation between changes in circulating EPC number and serum glucose level over the time course of 1, 4 and 7 days (Pearson correlation coefficient, *r* = --0.147, *P* = 0.019). EPC: Endothelial progenitor cell.](NRR-14-984-g004){#F3}

![High glucose levels reduce circulating EPCs numbers.\
The patients were divided into three subgroups according to elevated serum glucose levels at one day after traumatic brain injury and compared with normal control subjects by receiver operating characteristic curve analysis. Increased glucose of \< 0.92 mM is the lower glucose group; increased glucose of between 0.92 mM and 4.06 mM is the medium glucose group; increased glucose of \> 4.06 mM is the higher glucose group. The number of circulating EPCs for the first 4 days after traumatic brain injury was not obviously different among the three groups. The number of circulating EPCs was significantly decreased in higher serum glucose patients (*n* = 20) compared with lower (*n* = 29) or medium (*n* = 35) serum glucose patients. \#*P* \< 0.05, \#\#*P* \< 0.01, *vs*. higher glucose group. Data are expressed as the mean ± SEM (one-way analysis of variance followed by the Student-Newman-Keuls *post hoc* test). EPC: Endothelial progenitor cell.](NRR-14-984-g005){#F4}

Discussion {#sec1-4}
==========

This study first investigated the relationship between circulating EPCs and glucose levels after TBI. We found that increased glucose levels were negatively correlated with circulating EPC numbers within 7 days after TBI. EPC numbers were persistently increased in response to decreased blood glucose levels within 7 days after TBI. These data indicate that the decrease in circulating EPC numbers 24 hours after TBI may be caused by high blood glucose levels.

Since initial findings by Asahara et al. (1997), studies have concentrated on characterizing the abundance, phenotype and biochemical properties of circulating EPCs for potential therapeutic and diagnostic purposes. In this clinical investigation, we specifically examined dynamic changes in circulating EPCs in peripheral blood and the clinical significance for TBI. Consistent with our previous study of a smaller cohort of 29 patients (Liu et al., 2007), the number of circulating EPCs was first suppressed to 72.6% of the normal baseline number within the first 24 hours of TBI. This number then increased, reaching 173.1% of the baseline number at approximately 7 days before returning to baseline. These data indicate that circulating EPCs were suppressed after TBI. Initial EPC suppression is also reported in patients with ischemic stroke (Hou et al., 2015; Su et al., 2017) and is likely consumptive in nature as circulating EPCs accumulate at injured vascular beds. The reason for suppression of EPCs in peripheral blood after TBI is not fully understood. Many factors regulate EPC homing, migration and function. Many studies have shown that high glucose levels influence EPC homing, migration and function. To test the relationship between blood glucose and circulating EPC levels, we performed correlation analysis (Kim et al., 2015). We found that blood glucose levels were remarkably increased in patients at 24 hours after TBI, which was associated with decreased numbers of circulating EPCs. The dynamic change in circulating EPCs after TBI was negatively correlated with blood glucose levels. Previous studies have found that hyperglycemia induces reactive oxygen species and impairs EPCs (Lee et al., 2018). Hyperglycemia alters the differentiation fate of bone marrow derived EPCs, reducing the potential to generate vascular regenerative cells and favoring the development of proinflammatory cells (Wang et al., 2018a; Zheng et al., 2018). Higher glucose also accelerates the onset of EPC senescence, leading to impairment of proliferative activity, which is associated with the phosphorylation of p38 mitogen-activated protein kinase (Zhong et al., 2019). Therefore, increasing blood glucose levels may play a partial role in regulating circulating EPCs after TBI. Furthermore, compared with controls, EPC numbers were enhanced at 7--14 days after TBI. The blood glucose levels significantly decreased in patients at 7--14 days after TBI accompanied by increased numbers of circulating EPCs. A possible mechanism for this is that the lower blood glucose level attenuates the hyperglycemia-induced reactive oxygen species and the senescence of EPCs (Jacka et al., 2009).

There is a growing body of experimental and clinical evidence showing a significant association between persistent hyperglycemia and poor outcomes in different acute medical and surgical conditions (Solymar et al., 2018). Hyperglycemia is associated with worse outcome following TBI and cardiac surgery in adults (Sriganesh et al., 2012). Our pilot study showed that patients with worse clinical outcome or death had persistently low EPC numbers (data not shown). A key finding of the current study is that circulating EPC numbers are associated with blood glucose levels and clinical outcome of TBI. Therefore, the number of circulating EPCs may predict clinical outcome after TBI. However, the mechanisms of increasing EPCs to promote functional outcome after TBI are not fully understood. Increasing vascular remodeling and angiogenesis by bone marrow stromal cells or recombinant human erythropoietin promotes functional outcome after TBI (Madonna et al., 2017; Balistreri et al., 2018; Wang et al., 2018a). Vascular restoration after TBI-induced brain damage is crucial for reducing secondary ischemic injury after TBI. Circulating EPCs actively participate in tissue repair, largely through vascular repair and angiogenesis to restore blood flow to injured tissue. Circulating EPCs accumulate in the ischemic area to form new vessels and improve regional blood flow (Paynter et al., 2017). The number of circulating EPCs is negatively correlated with the size of ischemic area (Issan et al., 2013) and correlates with the Framingham risk score for ischemic stroke (Oishi et al., 2012). Yip et al. (2008) also showed that patients with severe neurological dysfunction (National Institutes of Health Stroke Scale score ± 12) have a lower number of circulating EPCs 48 hours post ischemic stroke. Increased numbers of circulating EPCs after acute ischemic stroke are associated with good functional outcome and reduced infarct growth. Our previous investigations found that increased numbers of circulating EPCs correlated with CD34 expression and angiogenesis in the brain after TBI (Jacka et al., 2009; Seal et al., 2018). Therefore, EPC regulation of vascular remodeling and angiogenesis might take part in neural repair after TBI.

In conclusion, we have shown a significant association between the numbers of circulating EPCs and blood glucose levels in 84 patients with TBI. The number of circulating EPCs was initially suppressed in the acute phase and then rapidly increased, reaching a peak 7 days after TBI. This pattern of change in circulating EPCs was negatively associated with blood glucose levels. Blood glucose levels were increased at 24 hours and returned back to normal 4 days after TBI. TBI patients with consistently low circulating EPC numbers and higher blood glucose levels were associated with worse clinical outcome or death. The numbers of circulating EPCs and blood glucose levels predicted the outcome after TBI. These results suggest that circulating EPCs may serve as a new clinical prognostic marker after TBI. In addition, increasing EPC mobilization and controlling glucose levels may improve clinical outcome in TBI patients.

A limitation of this study is observational investigation. A prospective research should be done in the future. In addition, the pre-traumatic blood glucose level in each patient was not determined. These factors influence the conclusion of this clinical investigation. Animal experiments should be conducted to verify whether hyperglycemia can inhibit the mobilization of EPCs.
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